Navigation Links
Sequenom, Inc. Reports Financial Results For The Third Quarter Of 2013
Date:11/7/2013

methods with discovery of a natural phenomenon fails to qualify as patent-eligible subject matter in accordance with Section 101 of the patent code.

"We believe the court's decision is wrong and misapplies or ignores controlling law," said Welch. "We believe that Drs. Lo and Wainscoat invented a novel method for detecting paternally inherited fetal DNA in maternal plasma and that their invention is more than just the discovery of a natural phenomenon. We intend to appeal the court's order to the United States Court of Appeals for the Federal Circuit."In August 2013, the United States Court of Appeals for the Federal Circuit, in a 3-0 decision, vacated the District Court's order denying the Company's motion for a preliminary injunction and corrected the District Court's preliminary claim construction. The October 30 summary judgment does not impact the current competitive landscape, as the Company has competed without the benefit of the patent being recognized.

Non-GAAP Financial Measures "GAAP" refers to financial information presented in accordance with generally accepted accounting principles in the United States. To supplement the condensed consolidated financial statements and discussion presented on a GAAP basis, this press release includes non-GAAP financial measures with respect to the quarter and nine months ended September 30, 2013. Management uses non-GAAP financial measures because it believes the appropriate analysis of our performance cannot be effectively considered while incorporating the effect of items and charges that have not been experienced consistently in prior periods. The Company reported the following non-GAAP financial measures: "adjusted net loss" and "adjusted net loss per share." These non-GAAP financial measures are not in accordance with or an alternative to GAAP.

Adjusted net earnings exclude the impact of charges associated with restructuring our operations including the impairment of intangible assets. Adjuste
'/>"/>

SOURCE Sequenom, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Sequenom, Inc. Announces Date Of Third Quarter 2013 Financial Results And Conference Call
2. Todays Research: Inovio Pharma, Sequenom, Peregrine Pharma, Onyx Pharma, and Optimer Pharma
3. Sequenom, Inc. Reports Financial Results For The First Quarter Of 2013
4. Morning Research on Sequenom, Peregrine Pharma, Onyx Pharma, and Inovio Pharma
5. Sequenom, Inc. Reports Financial Results For The Fourth Quarter And Full Year Of 2012
6. Sequenom, Inc. Announces Date Of Fourth Quarter And Full Year 2012 Financial Results And Conference Call
7. Sequenom, Inc. Reports Financial Results For The First Quarter Of 2012
8. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2013 Financial Results
9. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
10. ANI Pharmaceuticals Reports Net Revenues of $7.8 million, adjusted Non-GAAP EBITDA of $1.7 Million, and EPS of $0.13 for the Third Quarter Ended September 30, 2013
11. NxStage Reports Third Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014   Reproductive ... world-renowned leader in the field of infertility, presents ... to embryonic screening. The research abstract, released during ... Reproductive Medicine (ASRM) meeting in Honolulu, ... and single gene defect (SGD) pre-implantation genetic diagnosis ...
(Date:10/22/2014)... SAN DIEGO , Oct. 22, 2014 ... II medical device received 510 (k) OTC clearance by ... the AVACEN 100 to be marketed over the Internet ... with arthritis; muscle spasms; and minor strains and sprains ... The AVACEN 100 (MSRP $2495) is a ...
(Date:10/22/2014)... Pa. , Oct. 22, 2014  With ... their animal health medications, a Global Pharmaceutical and ... Antares serialization technology and turnkey solution to protect ... - http://photos.prnewswire.com/prnh/20141021/153438 Photo ... product that was serialized and aggregated by the ...
Breaking Medicine Technology:New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2Xyntek and Antares Serialization Solution Protects Pets Too! 2
... Breast cancer patients, their families and advocates expressed ... decision to remove the anti-cancer drug Avastin from the ... cancer. Terry Kalley, founder of the ... decision, saying, "While this vote is highly disappointing, it ...
... N.Y., Nov. 18, 2011  Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ... (FDA) has approved EYLEA (aflibercept) Injection, known in ... patients with neovascular (wet) Age-related Macular Degeneration (AMD) at a ... for the first 12 weeks, followed by 2 mg every ...
Cached Medicine Technology:Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration 2Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration 3Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration 4Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration 5Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration 6Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration 7Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration 8
(Date:10/22/2014)... RESTON, Va. (PRWEB) October 22, 2014 ... Healthcare Innovation , which is dedicated to distribute ... efficiency of healthcare delivery worldwide announced the development ... in which patients expect when receiving healthcare. These ... definition for patient-centered care: “providing care that is ...
(Date:10/22/2014)... 22, 2014 Best Cheap Hosting USA ... world. The site has recently announced that iPower ( ... for people from around the world. , “iPower is ... today and is providing various kinds of useful products ... insists on offering excellent customer service and a number ...
(Date:10/22/2014)... CA (PRWEB) October 22, 2014 Lintelus, ... Cormier, Sr. Vice President of Sales, will be speaking ... upcoming Meetings Technology Expo on October 28, at the ... be hosting a booth as well as a Tech ... Lintelus Meeting can create a more engaging event experience. ...
(Date:10/22/2014)... By Maureen Salamon ... -- Black women undergoing in vitro fertilization (IVF) are only ... using the popular assisted reproduction technique, new research indicates, and ... In the study, about 31 percent of white patients ... black patients. Analyzing more than 4,000 IVF cycles over ...
(Date:10/22/2014)... Oct. 21, 2014 (HealthDay News) -- Measures taken by ... in Ebola-ravaged Liberia may have limited the spread of ... report. The Firestone Natural Rubber Co. provides health ... residents of nearby densely populated communities. Between Aug. ... suspected Ebola cases among those 80,000 people. That incidence ...
Breaking Medicine News(10 mins):Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
... social science research organization NORC at the University of Chicago contradicts ... above age 80. It also explains why there ... and above than the Census Bureau predicted there would be as ... a new way of accurately measuring mortality of Americans who are ...
... at NYU Langone Medical Center will present their latest ... tendon, bone and joint at the annual meeting of ... in San Francisco, California. "The introduction ... in clinical care, allows our researchers to identify the ...
... a way to study how our brains assess the behavior ... Their study, described in a paper in the ... to use a computational approach to tease out differing patterns of ... compete against each other in a game, they try to make ...
... At a time when there is tremendous concern about ... and the costs of technology, the Canadian Institutes of ... to improve end of life decision making amongst seriously ... receiving funding for this initiative. , "Canada,s aging population ...
... Institutet, has received a grant of 1.6 million Euro ... the fundamental causes of diabetes. The grant will make ... the release of insulin is regulated in living organisms ... more effective drugs against diabetes. , Diabetes is an ...
... a few years, a new generation of easy-to-use blood-thinning drugs ... are at risk for stroke, according to a journal article ... new drugs do not require patients to come in to ... Nor do the drugs require extensive dietary restrictions. , First ...
Cached Medicine News:Health News:Odds of living a very long life lower than formerly predicted 2Health News:Odds of living a very long life lower than formerly predicted 3Health News:NYU Langone orthopaedic experts present research, clinical advances at AAOS meeting 2Health News:NYU Langone orthopaedic experts present research, clinical advances at AAOS meeting 3Health News:NYU Langone orthopaedic experts present research, clinical advances at AAOS meeting 4Health News:It's not solitaire: Brain activity differs when one plays against others 2Health News:CIHR invests in Queen's-led study on end-of-life decision making 2Health News:Donation opens new opportunities for more effective diabetes treatment 2Health News:Easy-to-use blood thinners likely to replace Coumadin 2
... Stellate Harmonie workstation is a medical device ... high quality video capability, and archiving demands ... review functions A framework that helps organize ... of data A centralized database and powerful ...
...
These are superior quality electrodes, fabricated from a single length of polyurethane tubing for strength and uniform smoothness. They are furnished with a specially-designed rigid stylet to facilit...
Integra Epilepsy grid electrodes are thin and flexible for easier placement and to conform to the curvature of the cortical surface. Lead tunneling is done using a 14-gauge tunneling needle (ET-2)....
Medicine Products: